Cite
HARVARD Citation
Andtbacka, R. et al. (2016). Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head & neck. 38 (12), pp. 1752-1758. [Online].